3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
47
enzalutamide
46
apalutamide
36
Specimen Handling
30
Androgen Antagonists
30
Abiraterone Acetate
29
Radiosurgery
26
Prednisone
25
darolutamide
24
Docetaxel
23
Pluvicto
21
abiraterone
19
Radiotherapy
19
Biopsy
17
Leuprolide
15
Surveys and Questionnaires
11
Radiation
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
11
relugolix
10
gallium 68 PSMA-11
10
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
10
Standard of Care
10
Nivolumab
10
cabazitaxel
9
Triptorelin Pamoate
9
bicalutamide
8
Carboplatin
8
pembrolizumab
7
olaparib
7
niraparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Serotonin 5-HT3 Receptor Antagonists
×
90 days
×
Clear all
NCT06925737
2026-05-29
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,440 enrolled